FORTESCUE METAL/S (FSUGY) and Opiant Pharmaceuticals (OPNT) Critical Review

Share on StockTwits

FORTESCUE METAL/S (OTCMKTS:FSUGY) and Opiant Pharmaceuticals (NASDAQ:OPNT) are both basic materials companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

Valuation and Earnings

This table compares FORTESCUE METAL/S and Opiant Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
FORTESCUE METAL/S $6.89 billion 1.32 $879.00 million $0.69 8.43
Opiant Pharmaceuticals $18.45 million 2.86 $6.58 million $2.94 6.02

FORTESCUE METAL/S has higher revenue and earnings than Opiant Pharmaceuticals. Opiant Pharmaceuticals is trading at a lower price-to-earnings ratio than FORTESCUE METAL/S, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

0.1% of FORTESCUE METAL/S shares are held by institutional investors. Comparatively, 4.5% of Opiant Pharmaceuticals shares are held by institutional investors. 37.9% of Opiant Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for FORTESCUE METAL/S and Opiant Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Opiant Pharmaceuticals 0 0 1 0 3.00

Opiant Pharmaceuticals has a consensus target price of $42.00, indicating a potential upside of 137.29%. Given Opiant Pharmaceuticals’ higher probable upside, analysts plainly believe Opiant Pharmaceuticals is more favorable than FORTESCUE METAL/S.

Volatility & Risk

FORTESCUE METAL/S has a beta of 1.94, indicating that its stock price is 94% more volatile than the S&P 500. Comparatively, Opiant Pharmaceuticals has a beta of 0.18, indicating that its stock price is 82% less volatile than the S&P 500.


This table compares FORTESCUE METAL/S and Opiant Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Opiant Pharmaceuticals -449.52% -471.43% -190.80%


FORTESCUE METAL/S pays an annual dividend of $0.31 per share and has a dividend yield of 5.3%. Opiant Pharmaceuticals does not pay a dividend. FORTESCUE METAL/S pays out 44.9% of its earnings in the form of a dividend.


FORTESCUE METAL/S beats Opiant Pharmaceuticals on 8 of the 15 factors compared between the two stocks.


Fortescue Metals Group Limited engages in the exploration, development, production, processing, and sale of iron ore in Australia, China, and internationally. The company owns and operates the Chichester Hub that includes the Cloudbreak and Christmas Creek mines located in the Chichester ranges; and the Solomon Hub comprising the Firetail and Kings Valley mines located in the Hamersley ranges of Pilbara, Western Australia. It is also developing the Eliwana mine situated in the Pilbara region of Western Australia. The company was founded in 2003 and is headquartered in East Perth, Australia.

Opiant Pharmaceuticals Company Profile

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine. Opiant Pharmaceuticals, Inc. has a collaboration agreement with Titan Pharmaceuticals, Inc. to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use disorder. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Santa Monica, California. Opiant Pharmaceuticals, Inc. is a subsidiary of Pelikin Group.

Receive News & Ratings for FORTESCUE METAL/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FORTESCUE METAL/S and related companies with's FREE daily email newsletter.

Leave a Reply